Received Mar 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | 3003852 | PO / MO |
The patient took Vivotif day one dose and day three dose two days in a row, as reported the first dose was yesterday and the second dose as today; Case reference number US-BN-2024-000100 is a spontaneous case report initially received from a nurse via Med Communication (reference number: USBAV24-0156) on 24-Jan-2024 and concerns a *68-year-old* male patient. *The patient had no relevant medical history.* The patient's concomitant medication details were not provided. On 23-Jan-2024, reported as yesterday, the patient took the first dose of Vivotif *(batch number: 3003852; expiration date: 31-Mar-2024) at a dose of one capsule,* orally, *for indication reported as travel.* On 24-Jan-2024, one day after the first dose of Vivotif, the patient took the second dose of Vivotif * (batch number: 3003852; expiration date: 31-Mar-2024) at a dose of one capsule,* orally. As reported, the patient took Vivotif day one dose and day three dose two days in a row (explicitly coded as 'inappropriate schedule of vaccine administered'). *As reported, the patient did not experience any adverse event due to Vivotif.* Additional information received from Bavarian Nordic on 24-Jan-2024 included local BN case ID. All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*). Follow-up information received from nurse on 28-Feb-2024: New information included patient demographic details, confirmation of no relevant medical history, Vivotif administration details for first and second dose and confirmation that the patient did not experience any adverse event due to Vivotif.; Reporter's Comments: A male patient of unspecified age took the second dose of Vivotif one day after the first dose, which is considered as inappropriate schedule of vaccine administered. The patient did not experience any adverse event due to Vivotif. Inappropriate schedule of vaccine administered is listed per company convention. The patient had no medical history and concomitant medication details were not provided. Inappropriate schedule of vaccine administered is not related to Vivotif, but to a human factor. The case is non-serious.; Sender's Comments: A male patient of unspecified age took the second dose of Vivotif one day after the first dose, which is considered as inappropriate schedule of vaccine administered. The patient did not experience any adverse event due to Vivotif. Inappropriate schedule of vaccine administered is listed per company convention. The patient had no medical history and concomitant medication details were not provided. Inappropriate schedule of vaccine administered is not related to Vivotif, but to a human factor. The case is non-serious.
Comments: None.